EDIT - Editas Medicine, Inc.
| Previous Close | 30.13 |
| Open | 30.33 |
| Bid | 28.63 x 2200 |
| Ask | 29.99 x 1000 |
| Day's Range | 29.59 - 30.56 |
| 52 Week Range | 17.80 - 31.78 |
| Volume | 702,872 |
| Avg. Volume | 797,649 |
| Market Cap | 1.5B |
| Beta (5Y Monthly) | 2.64 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.47 |
| Earnings Date | Feb 26, 2020 - Mar 2, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 46.71 |
- Zacks
Why Is Editas (EDIT) Up 28.7% Since Last Earnings Report?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire
Editas Medicine Announces In Vivo Proof-of-Concept Data for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia
Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced in vivo proof-of-concept data supporting the development of EDIT-301 as a potentially best-in-class, durable medicine to treat sickle cell disease and beta-thalassemia. EDIT-301 is the first experimental medicine in development using Cas12a (formerly known as Cpf1). The Company reported these data today at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) in Orlando, Fla.
- Thomson Reuters StreetEvents
Edited Transcript of EDIT earnings conference call or presentation 12-Nov-19 1:00pm GMT
Q3 2019 Editas Medicine Inc Earnings Call
- Zacks
Editas Medicine (EDIT) in Focus: Stock Moves 7.8% Higher
Editas Medicine (EDIT) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
- Zacks
Vertex, CRISPR's Gene Editing Drug Shows Positive Early Data
Vertex (VRTX) and partner CRISPR Therapeutics announce positive early data from two studies on gene-editing drug CTX001 for the treatment of beta-thalassemia and sickle cell disease.
- American City Business Journals
CRISPR Therapeutics stock jumps on early gene editing data
CRISPR Therapeutics and Vertex Pharmaceuticals released the first data from their early-stage trial testing the safety and effectiveness of a potential cure for the genetic blood disorders sickle cell disease and beta thalassemia.
- Zacks
Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal
Editas' (EDIT) portfolio currently lacks an approved product. The focus of third-quarter earnings call was on its pipeline development.
- Zacks
Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of 9.59% and -6.38%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Editas Medicine Announces Third Quarter 2019 Results and Update
Amended Celgene collaboration to focus on engineered alpha-beta T cell medicines with a $70 million payment to Editas Medicine Appointed Judith R. Abrams, M.D., as Chief.
- GlobeNewswire
Editas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune Diseases
Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced an amended collaboration with Celgene Corporation (CELG) under which the parties may research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. Under the terms of the amended agreement, Editas Medicine will receive a payment of $70 million. “Celgene is the leader in advancing innovative cell medicines to treat blood cancers, and we are excited to expand our productive working relationship with the Celgene team as we increase our commitment to advancing gene-edited cell medicines in oncology and beyond,” said Charles Albright, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine.
- GlobeNewswire
Editas Medicine to Host Conference Call Discussing Third Quarter 2019 Results and Corporate Update
CAMBRIDGE, Mass., Nov. 05, 2019 -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on.
- Investopedia
8 Undervalued Biotech Stocks to Watch Now
As investors shift out of growth names and to more defensive pockets of the market, market watchers now see these biotech players as undervalued.
- Zacks
Analysts Estimate Editas Medicine (EDIT) to Report a Decline in Earnings: What to Look Out for
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Barrons.com
Experts Talk Hot Biotech Stocks at Barron’s Breakfast
The conversation came at a pivotal moment for the sector, as biotech stocks stage a comeback following a weak year.
- GlobeNewswire
Editas Medicine Appoints Judith R. Abrams, M.D., as Chief Medical Officer
Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced that it named Judith R. Abrams, M.D., as the Company’s Chief Medical Officer, effective immediately. Dr. Abrams is a leading drug development clinician who has brought multiple medicines from clinical stage development to regulatory approval. “We are delighted to have Judith join our leadership at this important juncture for the Company with the recent initiation of the Phase 1/2 Brilliance trial of EDIT-101 (AGN-151587) for the treatment of patients with Leber congenital amaurosis 10 (LCA10),” said Cynthia Collins, President and Chief Executive Officer, Editas Medicine.
- Insider Monkey
Is Editas Medicine, Inc. (EDIT) Going to Burn These Hedge Funds?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]
- Zacks
Moving Average Crossover Alert: Editas Medicine
Editas Medicine, Inc. (EDIT) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
- Simply Wall St.
Companies Like Editas Medicine (NASDAQ:EDIT) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
- Zacks
Editas Inks Deal for Gene Editing Neurological Disease Drugs
Editas (EDIT) and privately held Asklepios BioPharmaceutical will collaborate on exploring in vivo delivery of genome editing medicines to treat neurological diseases.
- Zacks
CRISPR Therapeutics Enters New License Agreement, Shares Up
CRISPR Therapeutics (CRSP) looks to strengthen its CAR-T therapy programs through its agreement with KSQ Therapeutics.
- GlobeNewswire
Editas Medicine and AskBio Enter Strategic Research Collaboration to Explore In Vivo Delivery of Genome Editing Medicines to Treat Neurological Diseases
CAMBRIDGE, Mass. and RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2019 -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Asklepios BioPharmaceutical,.
- GlobeNewswire
Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines
Editas Medicine, Inc. (EDIT), a leading genome editing company, and MaxCyte, Inc., the global cell-based therapies and life sciences company, today announced a new clinical and commercial license agreement. Editas Medicine will use MaxCyte’s Flow Electroporation® technology and ExPERT™ instruments for the advancement of engineered cell medicines, including EDIT-301, an experimental CRISPR medicine designed to durably treat sickle cell disease and beta-thalassemia. Under the terms of the agreement, Editas Medicine obtains non-exclusive clinical and commercial use rights to MaxCyte's cell engineering platform to develop up to five therapies including four immuno-oncology therapies, and in return MaxCyte will receive development and approval milestones and sales-based payments in addition to other licensing fees.
- GlobeNewswire
Editas Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Oct. 01, 2019 -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following.
